myNAT™ – Affordable, Open, and Fully Automated Sample-to-Answer PCR Panel Testing
OnsiteGene proudly presents myNAT™, a next-generation molecular diagnostic platform that brings laboratory-grade multiplex PCR panel testing into compact, cost-effective, and field-deployable form. Designed for 35-minute sample-to-answer workflows, myNAT™ integrates magnetic bead nucleic acid extraction and real-time PCR with melt curve analysis—all within a closed, ultra-low-cost cartridge that requires no cold-chain logistics.

Unlike traditional systems, myNAT™ features an open platform design, allowing users to load their own reagents or choose from OnsiteGene’s growing menu of infectious disease, antimicrobial resistance, GI, and syndromic panels. Each cartridge supports up to 20 targets across 4 PCR tubes, expandable to 40-plex, with full compatibility for swabs, saliva, sputum, blood, urine, tissue, and more.

Selected for the NIH RADx Advanced Diagnostics Program, myNAT™ redefines affordability, flexibility, and scalability in decentralized molecular testing.

Key Features:
  • Automated Sample-to-Answer Workflow: 35-minute turnaround, with 5–10 minute target in development
  • Open Cartridge Design: Load user reagents or use OnsiteGene’s RUO panel kits
  • Flexible Multiplexing: 1–20 targets per run, expandable to 40-plex
  • Room Temperature Storage: Cartridges and reagents stable for 12 months
  • Compact & Lightweight: Only 7.6 kg; ideal for POC, mobile, or low-resource settings
  • Scalable Operation: Run up to 64 samples simultaneously via multi-unit configurations
  • Broad Applications: Infectious disease, AMR screening, food safety, vet diagnostics, LDTs, and more
Visit Booth #416 at ADLM 2025 to see how myNAT™ is bringing rapid, affordable, open-panel PCR testing to the point of need—empowering users worldwide to run what they need, where they need it.
Category Press Releases
Added by OnsiteGene, Inc.